The share price of Protalix BioTherapeutics (NYSEMKT:PLX) is off more than 43% in pre-market trading on Wednesday morning after the Israeli biopharma got word that the U.S. Food and Drug ...
Fabry disease is a rare genetic lysosomal storage disorder in which the body lacks sufficient amounts of an enzyme that breaks down fats. The companies requested to approve the dosing regimen of 2 ...
Protalix received FDA and EU approval for Elfabrio. This puts the company on track for profitability as early as 2023. With a reasonable valuation and strong growth, I see a significant potential ...
We recently published a list of 10 Best Rated Penny Stocks To Buy According to Analysts. In this article, we are going to take a look at where Protalix BioTherapeutics, Inc. (NYSE:PLX) stands against ...
Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is among the hidden penny stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Protalix BioTherapeutics, Inc ...
Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results